WO2006013546A3 - Process for the preparation of pure galantamine - Google Patents
Process for the preparation of pure galantamine Download PDFInfo
- Publication number
- WO2006013546A3 WO2006013546A3 PCT/IB2005/052553 IB2005052553W WO2006013546A3 WO 2006013546 A3 WO2006013546 A3 WO 2006013546A3 IB 2005052553 W IB2005052553 W IB 2005052553W WO 2006013546 A3 WO2006013546 A3 WO 2006013546A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- preparation
- galantamine
- pure
- pure galantamine
- relates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN1393DE2004 | 2004-07-28 | ||
IN1393/DEL/2004 | 2004-07-28 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2006013546A2 WO2006013546A2 (en) | 2006-02-09 |
WO2006013546A3 true WO2006013546A3 (en) | 2006-05-11 |
Family
ID=35285287
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2005/052553 WO2006013546A2 (en) | 2004-07-28 | 2005-07-28 | Process for the preparation of pure galantamine |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2006013546A2 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102050826B (en) * | 2010-12-21 | 2012-11-14 | 浙江工业大学 | Method for separating galanthamine |
CN104177368B (en) * | 2014-05-27 | 2016-06-08 | 天津梅花医药有限公司 | A kind of galanthamine hydrobromide compound, preparation method and pharmaceutical composition thereof |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996012692A1 (en) * | 1994-10-21 | 1996-05-02 | Waldheim Pharmazeutika Gesellschaft M.B.H. | PROCESS FOR PRODUCING DERIVATIVES OF 4a,5,9,10,11,12,-HEXAHYDRO-6H-BENZOFURO[3a,3,2-ef][2]BENZAZEPINE |
AT401058B (en) * | 1994-10-21 | 1996-06-25 | Waldheim Pharmazeutika Gmbh | Process for the preparation of derivatives of 4a, 5, 9, 10, 11, 12-hexahydro-6H-benzofuro(3a, 3, 2- ef)(2)benzazepine |
US5877172A (en) * | 1995-03-17 | 1999-03-02 | Lts Lohmann Therapie-Systeme Gmbh | Process for isolating galanthamine |
WO2000030446A1 (en) * | 1998-11-23 | 2000-06-02 | Bonnie Davis | Dosage formulations for acetylcholinesterase inhibitors |
US6087495A (en) * | 1996-01-04 | 2000-07-11 | Janssen Pharmaceutica, N.V. | Process for the preparation of galanthamine |
US6346618B1 (en) * | 1996-05-24 | 2002-02-12 | Janssen Pharmaceutica N.V. | Optical resolution of narwedine-type compounds |
US20030225031A1 (en) * | 2002-05-21 | 2003-12-04 | Quay Steven C. | Administration of acetylcholinesterase inhibitors to the cerebral spinal fluid |
US20040097484A1 (en) * | 2002-11-14 | 2004-05-20 | Marc Cantillion | Once a day galantamine pharmaceutical compositions and methods of use |
WO2004075916A1 (en) * | 2003-02-27 | 2004-09-10 | Shirankai Kyoto University Faculty Of Medicine Alumni Association Inc. | Pharmaceutical composition for treatment of drug dependence |
WO2005065661A2 (en) * | 2003-12-31 | 2005-07-21 | Actavis Group Hf | Immediate, controlled and sustained release formulations of galanthamine |
-
2005
- 2005-07-28 WO PCT/IB2005/052553 patent/WO2006013546A2/en active Application Filing
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996012692A1 (en) * | 1994-10-21 | 1996-05-02 | Waldheim Pharmazeutika Gesellschaft M.B.H. | PROCESS FOR PRODUCING DERIVATIVES OF 4a,5,9,10,11,12,-HEXAHYDRO-6H-BENZOFURO[3a,3,2-ef][2]BENZAZEPINE |
AT401058B (en) * | 1994-10-21 | 1996-06-25 | Waldheim Pharmazeutika Gmbh | Process for the preparation of derivatives of 4a, 5, 9, 10, 11, 12-hexahydro-6H-benzofuro(3a, 3, 2- ef)(2)benzazepine |
US5877172A (en) * | 1995-03-17 | 1999-03-02 | Lts Lohmann Therapie-Systeme Gmbh | Process for isolating galanthamine |
US6087495A (en) * | 1996-01-04 | 2000-07-11 | Janssen Pharmaceutica, N.V. | Process for the preparation of galanthamine |
US6346618B1 (en) * | 1996-05-24 | 2002-02-12 | Janssen Pharmaceutica N.V. | Optical resolution of narwedine-type compounds |
WO2000030446A1 (en) * | 1998-11-23 | 2000-06-02 | Bonnie Davis | Dosage formulations for acetylcholinesterase inhibitors |
US20030225031A1 (en) * | 2002-05-21 | 2003-12-04 | Quay Steven C. | Administration of acetylcholinesterase inhibitors to the cerebral spinal fluid |
WO2004002402A2 (en) * | 2002-05-21 | 2004-01-08 | Nastech Pharmaceutical Company Inc. | Administration of acetylcholinesterase inhibitors to the cerebral spinal fluid |
US20040097484A1 (en) * | 2002-11-14 | 2004-05-20 | Marc Cantillion | Once a day galantamine pharmaceutical compositions and methods of use |
WO2004075916A1 (en) * | 2003-02-27 | 2004-09-10 | Shirankai Kyoto University Faculty Of Medicine Alumni Association Inc. | Pharmaceutical composition for treatment of drug dependence |
WO2005065661A2 (en) * | 2003-12-31 | 2005-07-21 | Actavis Group Hf | Immediate, controlled and sustained release formulations of galanthamine |
US20050191349A1 (en) * | 2003-12-31 | 2005-09-01 | Garth Boehm | Galantamine formulations |
Non-Patent Citations (2)
Title |
---|
KAMETANI T ET AL: "THE OPTICAL RESOLUTION OF ( )-GALANTHAMINE", HETEROCYCLES, vol. 4, no. 6, 1976, pages 1111 - 1114, XP000603575, ISSN: 0385-5414 * |
SZEWCZYK, WILSON, LEWIN, CAROLL, J. HETEROCYCLIC CHEM., vol. 32, 1995, pages 195 - 199, XP002354925 * |
Also Published As
Publication number | Publication date |
---|---|
WO2006013546A2 (en) | 2006-02-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004074232A8 (en) | 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases | |
WO2007058602A3 (en) | Novel 2-amino-imidazole-4-one compounds and their use in the manufacture of a medicament to be used in the treatment of cognitive impairment, alzheimer’s disease, neurodegeneration and dementia. | |
WO2006001877A3 (en) | Combination treatment for neurodegenerative disorders comprising r-flurbiprofen | |
WO2004062625A3 (en) | Macrocyclic beta-secretase inhibitors for treatment of alzheimer's disease | |
WO2004071431A3 (en) | Method and composition for treating neurodegenerative disorders | |
WO2005032471A3 (en) | Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease | |
WO2005004803A3 (en) | Phenylcarboxylate beta-secretase inhibitors for the treatment of alzheimer's disease | |
EP1940373B8 (en) | 1-fluoro-1-deoxy-scyllo-inositol for the treatment of alzheimer's disease | |
WO2005004802A3 (en) | N-alkyl phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer's disease | |
EP2213684A3 (en) | Nogo-a antibodies for the treatment of Alzheimer disease | |
WO2006096439A3 (en) | Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases | |
WO2007038112A3 (en) | Combination of rosiglitazone and donepezil for improvement of cognitive function | |
WO2005018545A3 (en) | Macrocyclic beta-secretase inhibitors for the treatment of alzheimer's disease | |
WO2008076392A3 (en) | Compounds useful as protein kinase inhibitors | |
IL177787A0 (en) | 1-aminovyclohexane derivatives for the treatment of agitation and other behavioral disorders, especially those associated with alzheimer's disease | |
WO2005051914A8 (en) | Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease | |
MY134480A (en) | 4-pyrrolidino-phenyl-benzyl ether derivatives | |
WO2006078576A3 (en) | Aminomethyl beta-secretase inhibitors for the treatment of alzheimer's disease | |
IL188752A0 (en) | Pharmaceutical compositions comprising a tungsten salt (vi) for the treatment of neurodegenerative disorders, particularly alzheimer's disease and schizophrenia | |
WO2007058805A3 (en) | Compositions and methods for treating cns disorders | |
WO2001053457A3 (en) | Vaccines against neurodegenerative disorders | |
HK1104280A1 (en) | Derivatives of 1-phenylalkanecarboxylic acids for the treatment of neurodegenerative diseases | |
WO2007017146A3 (en) | Use of collismycin and derivatives thereof as oxidative stress inhibitors | |
WO2007144699A3 (en) | Process for the preparation of alfuzosin | |
WO2006013546A3 (en) | Process for the preparation of pure galantamine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1277/DELNP/2007 Country of ref document: IN |
|
122 | Ep: pct application non-entry in european phase |